Monthly Archives: February 2022
POPULATION PHARMACOKINETICS OF OZANIMOD AND ACTIVE METABOLITE CC112273 IN PATIENTS WITH ULCERATIVE COLITIS
Ozanimod is an oral small molecule sphingosine 1-phosphate receptor modulator approved for relapsing forms of multiple sclerosis (RMS) and moderately to severely active ulcerative colitis (UC) and under development for Crohn’s disease (CD). Following m… Continue reading
IMPACT OF TIMING OF INITIATION OF INFLIXIMAB ON THE RISK OF IBD-RELATED SURGERY AND COMPLICATIONS
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal system. Approximately 20% of new diagnoses are pediatric patients. Treatment for pediatric IBD has changed in recent years, focusing on decreased… Continue reading
DEVELOPMENT AND VALIDATION OF THE CROHN’S DISEASE-HEALTH INDEX (CD-HI), A CLINICALLY-RELEVANT, DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME MEASURE
The goal of this research is to develop and validate a novel, disease-specific patient-reported outcome measure (PROM) for use in clinical monitoring and therapeutic trials of Crohn’s Disease (CD). Continue reading
VEDOLIZUMAB FOR REFRACTORY MICROSCOPIC COLITIS: A CASE SERIES
Microscopic colitis (MC) is a chronic inflammatory disease of the colon that causes non-bloody, watery diarrhea occurs up to 15 times daily in the presence of normal-appearing mucosa in the colon. There are two main subtypes of MC based on histopatholo… Continue reading
COMPARISON OF THE INFLAMMATORY BOWEL DISEASES PHENOTYPE AND COURSE IN THE ELDERLY- AND EARLY-ONSET PATIENTS
It is unknown if clinical phenotype and course of the disease are comparable between early- and elderly-onset inflammatory bowel diseases (IBD). There is also an ongoing dispute on whether elderly-onset IBD is a separate entity. We aimed to seek differ… Continue reading
SUCCESSFUL CLEARANCE OF CYTOMEGALOVIRUS COLITIS IN ACUTE SEVERE ULCERATIVE COLITIS DURING INDUCTION OF OZANIMOD
Cytomegalovirus (CMV) colitis, commonly observed in patients with acute severe ulcerative colitis (UC), increases the risk for colectomy and treatment resistance. Unfortunately, corticosteroids and immunomodulators increase CMV reactivation and infecti… Continue reading
CLINICAL FEATURES AND OUTCOMES OF PAEDIATRIC PATIENTS WITH ISOLATED COLONIC CROHN’S DISEASE: A MULTICENTRE STUDY FROM THE PAEDIATRIC IBD PORTO GROUP OF ESPGHAN
Adult studies suggest that patients with isolated colonic Crohn’s disease (L2 CD) exhibit unique characteristics differentiating them from patients with ileo-cecal (L1) CD and ulcerative colitis (UC). We aimed to characterize clinical features and outc… Continue reading
REAL WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD: INITIAL RESULTS FROM A LARGE TERTIARY CENTER
In May 2021 the United Stated Food and Drug Administration (FDA) approved the use of ozanimod for moderate to severe ulcerative colitis (UC) based on the results of the pivotal phase 3 TRUE NORTH trials. We present the first report of real world data d… Continue reading
TRENDS IN ADMISSIONS, OUTCOMES AND FINANCIAL BURDEN OF C. DIFFICILE INFECTION RELATED HOSPITALIZATIONS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS: A NATIONWIDE ANALYSIS
Inflammatory bowel disease (IBD) patients with colonic involvement are known to have microbiome changes which may increase their risk of C. difficile infection (CDI). We conducted an analysis to describe the implications of CDI on hospitalized IBD pati… Continue reading